中国医药科学
中國醫藥科學
중국의약과학
CHINA MEDICINE AND PHARMACY
2013年
15期
16-18
,共3页
GJB2%突变%非综合征性耳聋%meta分析
GJB2%突變%非綜閤徵性耳聾%meta分析
GJB2%돌변%비종합정성이롱%meta분석
GJB2%Mutation%Non-syndromic hearing loss%Meta-analysis
目的探讨我国人群GJB2基因235delC突变与非综合征性耳聋的相关性。方法采用固定效应模型对国内外公开发表的中国人群GJB2基因235delC突变与非综合征性耳聋患者相关性的病例对照研究进行meta分析。结果该meta分析共纳入文献22篇。合并效应量：OR=11.375（Z=16.34，P=0.00，95%可信区间为8.497～15.227）。异质性检验：x2=27.95，P=0.142，I2=24.9%。出版偏倚：Z=0.70，P=0.481。结论 GJB2基因235delC突变是导致NSHL的重要危险因子，在新生儿听力筛查中应重视该基因突变的检测。
目的探討我國人群GJB2基因235delC突變與非綜閤徵性耳聾的相關性。方法採用固定效應模型對國內外公開髮錶的中國人群GJB2基因235delC突變與非綜閤徵性耳聾患者相關性的病例對照研究進行meta分析。結果該meta分析共納入文獻22篇。閤併效應量：OR=11.375（Z=16.34，P=0.00，95%可信區間為8.497～15.227）。異質性檢驗：x2=27.95，P=0.142，I2=24.9%。齣版偏倚：Z=0.70，P=0.481。結論 GJB2基因235delC突變是導緻NSHL的重要危險因子，在新生兒聽力篩查中應重視該基因突變的檢測。
목적탐토아국인군GJB2기인235delC돌변여비종합정성이롱적상관성。방법채용고정효응모형대국내외공개발표적중국인군GJB2기인235delC돌변여비종합정성이롱환자상관성적병례대조연구진행meta분석。결과해meta분석공납입문헌22편。합병효응량：OR=11.375（Z=16.34，P=0.00，95%가신구간위8.497～15.227）。이질성검험：x2=27.95，P=0.142，I2=24.9%。출판편의：Z=0.70，P=0.481。결론 GJB2기인235delC돌변시도치NSHL적중요위험인자，재신생인은력사사중응중시해기인돌변적검측。
Objective To investigate the association between GJB2 gene 235delC mutation and risk for non-syndromic hearing loss (NSHL) in Chinese population. Methods To perform a meta-analysis with fixed-effect model on published case-control study addressing association between GJB2 gene 235delC mutation and risk for non-syndromic hearing loss in Chinese population. Results A total of 22 articles were included in the meta-analysis. The pooled OR=11.375 (Z=16.34,P=0.00,95% confidence interval: 8.497-15.227). Heterogeneity test:x2=27.95, P=0.142,I2=24.9%. Publication bias test:Z=0.70,P=0.481. Conclusion GJB2 gene 235delC mutation is a very important risk factor for the development of NSHL. Great attention should be paid on GJB2 gene 235delC mutation screening for the purpose of preventing NSHL in Chinese population.
